title: Retreatment efficacy and safety of tocilizumab in patients with rheumatoid arthritis in recurrence (RESTORE) study.
abstract: OBJECTIVE
  To evaluate the safety and efficacy of retreatment with tocilizumab (TCZ) in patients who had participated in the DREAM study (Drug free remission/low disease activity after cessation of tocilizumab [Actemar] monotherapy study) and had experienced loss of efficacy.
  
  
  METHODS
  Patients were retreated with TCZ or other disease modifying antirheumatic drugs (DMARDs). Disease activity was measured using the 28-joint disease activity score (DAS28) for 12 weeks.
  
  
  RESULTS
  A total of 164 eligible patients, including 161 who experienced loss of efficacy within 52 weeks of the DREAM study, resumed treatment: 157 with TCZ and 7 with DMARDs and/or infliximab. Of TCZ-treated patients, 88.5 % (139 patients) achieved DAS28 <2.6 within 12 weeks, whereas among patients treated with DMARDs and/or infliximab only 14.3 % (1 patient) achieved DAS28 <2.6. Adverse events were observed in 70 TCZ-treated patients (44.0 %), but no serious infusion reactions were observed.
  
  
  CONCLUSIONS
  Retreatment with TCZ was well-tolerated and effective in patients who had responded to the preceding TCZ monotherapy but had experienced loss of efficacy after cessation of TCZ.
authors.affiliation: Osaka Rheumatology Clinic , Tatsuno-Sinsaibashi-Building 5th Floor, 4-4-10 Minamisenba Chuo-ku, Osaka 542-0081 , Japan.
authors.forename: Norihiro
authors.initials: N
authors.lastname: Nishimoto
authors.forename: Koichi
authors.initials: K
authors.lastname: Amano
authors.forename: Yasuhiko
authors.initials: Y
authors.lastname: Hirabayashi
authors.forename: Takahiko
authors.initials: T
authors.lastname: Horiuchi
authors.forename: Tomonori
authors.initials: T
authors.lastname: Ishii
authors.forename: Mitsuhiro
authors.initials: M
authors.lastname: Iwahashi
authors.forename: Masahiro
authors.initials: M
authors.lastname: Iwamoto
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Kohsaka
authors.forename: Masakazu
authors.initials: M
authors.lastname: Kondo
authors.forename: Tsukasa
authors.initials: T
authors.lastname: Matsubara
authors.forename: Toshihide
authors.initials: T
authors.lastname: Mimura
authors.forename: Hisaaki
authors.initials: H
authors.lastname: Miyahara
authors.forename: Shuji
authors.initials: S
authors.lastname: Ohta
authors.forename: Yukihiko
authors.initials: Y
authors.lastname: Saeki
authors.forename: Kazuyoshi
authors.initials: K
authors.lastname: Saito
authors.forename: Hajime
authors.initials: H
authors.lastname: Sano
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Takasugi
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Takeuchi
authors.forename: Shigeto
authors.initials: S
authors.lastname: Tohma
authors.forename: Tomomi
authors.initials: T
authors.lastname: Tsuru
authors.forename: Yukitaka
authors.initials: Y
authors.lastname: Ueki
authors.forename: Jiro
authors.initials: J
authors.lastname: Yamana
authors.forename: Jun
authors.initials: J
authors.lastname: Hashimoto
authors.forename: Takaji
authors.initials: T
authors.lastname: Matsutani
authors.forename: Miho
authors.initials: M
authors.lastname: Murakami
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Takagi
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D019233:Retreatment; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D000069285:Infliximab; C502936:tocilizumab